Hao Sun1, Bin Zhang1, Xinxin Jiang2, Honglian Liu1, Shengming Deng1, Zhen Li2, Haibin Shi2. 1. Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou 215006, China. 2. State Key Laboratory of Radiation Medicine & Protection, School for Radiological & Interdisciplinary Sciences (RAD-X) & Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
Abstract
AIM: In the present study, we aimed to characterize the tumor-targeting properties of ultra-small iron oxide nanoparticles (IONPs) as multimodality imaging contrast agent. METHODS: The dimeric cRGD peptides [cyclic(Cys-Arg-Gly-Asp-dSer-Cys)-Tyr-dSer-Lys-Tyr-cyclic(Cys-Arg-Gly-Asp-dSer-Cys)], which specifically targeted integrin-αvβ3 receptor highly overexpressed in tumor vasculature and tumor cells, were covalently conjugated onto the surface of ultra-small IONPs followed by the labeling of nuclide 125I- through the chloramine-T method to afford the desired 125I-(cRGD)2-IONPs nanoprobe.125I-(cRGD)2-IONPs were injected into tumor-bearing mice for magnetic resonance (MR) and single photon emission computed tomography (SPECT) multi-modality imaging of tumors. RESULTS: The prepared IONPs demonstrated were very useful for T1/T2 and SPECT imaging of tumors in vivo, exhibiting a high tumor uptake of a clinically useful target-to-background ratio in a short time. CONCLUSION: We successfully developed a novel integrin-αvβ3 receptor-targeted ultra-small IONPs, which could be successfully used as T1-T2-MRI/SPECT contrast agents for high-resolution and high-sensitivity of tumor imaging in vivo.
AIM: In the present study, we aimed to characterize the tumor-targeting properties of ultra-small iron oxide nanoparticles (IONPs) as multimodality imaging contrast agent. METHODS: The dimeric cRGD peptides [cyclic(Cys-Arg-Gly-Asp-dSer-Cys)-Tyr-dSer-Lys-Tyr-cyclic(Cys-Arg-Gly-Asp-dSer-Cys)], which specifically targeted integrin-αvβ3 receptor highly overexpressed in tumor vasculature and tumor cells, were covalently conjugated onto the surface of ultra-small IONPs followed by the labeling of nuclide 125I- through the chloramine-T method to afford the desired 125I-(cRGD)2-IONPs nanoprobe.125I-(cRGD)2-IONPs were injected into tumor-bearing mice for magnetic resonance (MR) and single photon emission computed tomography (SPECT) multi-modality imaging of tumors. RESULTS: The prepared IONPs demonstrated were very useful for T1/T2 and SPECT imaging of tumors in vivo, exhibiting a high tumor uptake of a clinically useful target-to-background ratio in a short time. CONCLUSION: We successfully developed a novel integrin-αvβ3 receptor-targeted ultra-small IONPs, which could be successfully used as T1-T2-MRI/SPECT contrast agents for high-resolution and high-sensitivity of tumor imaging in vivo.
Entities:
Keywords:
MRI; dimeric cRGD peptide; integrin αβ ; iron oxide NPs; multimodal imaging; single photon emission computed tomography; tumor targeting